Abstract: Provided are a biomarker for evaluating a cerebral A? accumulation state using an amyloid precursor protein (APP)-derived peptide in a living body-derived sample as an index, and a method for analysis thereof. A living body-derived sample derived from a test subject is measured, and at least one ratio selected from the group consisting of APP669-711/APP672-713 (A?1-42); APP672-709 (A?1-38)/APP672-713 (A?1-42); APP674-711 (A?3-40)/APP672-713 (A?1-42); APP672-710 (A?1-39)/APP672-713 (A?1-42); APP672-711 (A?1-40)/APP672-713 (A?1-42); and APP672-711 (OxA?1-40)/APP672-713 (A?1-42) is calculated, and when each of the ratios of the test subject is higher than each of standard levels which are ratios of a person having normal cognitive function NC? who is negative for cerebral A? accumulation, an accumulation amount of cerebral A? of the test subject is determined as larger than an accumulation amount of cerebral A? of the person having normal cognitive function NC?.

Abstract: The present invention provides a transgenic invertebrate model for Alzheimer's disease and a method for screening a therapeutic agent for Alzheimer's disease using the model. The present invention provides a transgenic invertebrate, in which genes encoding enzymes involved in production of a ganglioside are introduced and the ganglioside is expressed.

Abstract: A three-dimensional object data generation apparatus includes an obtaining unit that obtains three-dimensional object data regarding a three-dimensional object represented by plural first voxels for which a first attribute is set and a replacement unit that, if the first attribute is different from a second attribute achievable by a three-dimensional object forming apparatus that forms the three-dimensional object, replaces each of the plural first voxels with plural second voxels for which the second attribute is set such that the plural second voxels become equivalent to the first voxel.

Abstract: A three-dimensional object data generation apparatus includes an obtaining unit that obtains three-dimensional object data regarding a three-dimensional object represented by plural first voxels for which a first attribute is set and a replacement unit that, if the first attribute is different from a second attribute achievable by a three-dimensional object forming apparatus that forms the three-dimensional object, replaces each of the plural first voxels with plural second voxels for which the second attribute is set such that the plural second voxels become equivalent to the first voxel.

Abstract: An amyloid fibril formation inhibitor comprising a compound represented by the following general formulae (I) to (III): wherein Q is —C(?O)—; X is —C(?O)—, —NH—C(?O)—; Y is —(CH2)m—; Z is —(CH2)n—; R1, R2, and R3 are each independently a hydrogen atom, an alkyl group, a hydroxyalkyl group, an alkylaminoalkyl group; and R4 is an amino group, an alkylamino group or the like; or a pharmaceutically acceptable salt thereof or a solvate thereof.

Abstract: An amyloid fibril formation inhibitor comprising a compound represented by the following general formulae (I) to (III): wherein Q is —C(?O)—; X is —C(?O)—, —NH—C(?O)—; Y is —(CH2)m—; Z is —(CH2)n—; R1, R2, and R3 are each independently a hydrogen atom, an alkyl group, a hydroxyalkyl group, an alkylaminoalkyl group; and R4 is an amino group, an alkylamino group or the like; or a pharmaceutically acceptable salt thereof or a solvate thereof.

Abstract: Provided are a biomarker for evaluating a cerebral A? accumulation state using an amyloid precursor protein (APP)-derived peptide in a living body-derived sample as an index, and a method for analysis thereof. A living body-derived sample derived from a test subject is measured, and at least one ratio selected from the group consisting of APP669-711/APP672-713 (A?1-42); APP672-709 (A?1-38)/APP672-713 (A?1-42); APP674-711 (A?3-40)/APP672-713 (A?1-42); APP672-710 (A?1-39)/APP672-713 (A?1-42); APP672-711 (A?1-40)/APP672-713 (A?1-42); and APP672-711 (OxA?1-40)/APP672-713 (A?1-42) is calculated, and when each of the ratios of the test subject is higher than each of standard levels which are ratios of a person having normal cognitive function NC? who is negative for cerebral A? accumulation, an accumulation amount of cerebral A? of the test subject is determined as larger than an accumulation amount of cerebral A? of the person having normal cognitive function NC?.

Abstract: Disclosed is an antibody having a high inhibitory effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided.

Abstract: Disclosed is an antibody having a high inhibitory effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided.

Abstract: Disclosed is an antibody having a high inhibitor effect on amyloid fibril formation. An antibody is produced by using a liposome containing a GM1 ganglioside at a predetermined ratio as an immunogen. Thus, the sequences of four types of antibodies each having a high inhibitory effect on amyloid fibril formation can be provided.

Abstract: It is intended to provide an antibody efficacious in diagnosing, preventing or treating Alzheimer's disease, DNA encoding the antibody, a method of screening a drug and drugs. The amino acid sequence and the gene sequence of the variable region of an antibody, which specifically recognizes a GM1 ganglioside-bound amyloid ?-protein occurring in the early stage of ?-amyloid fibril formation, are determined. Based on the data of the amino acid sequence and the gene sequence thus obtained, an antibody is designed.

Abstract: It is intended to provide an antibody efficacious in diagnosing, preventing or treating Alzheimer's disease, DNA encoding the antibody, a method of screening a drug and drugs. The amino acid sequence and the gene sequence of the variable region of an antibody, which specifically recognizes a GM1 ganglioside-bound amyloid &bgr;-protein occurring in the early stage of &bgr;-amyloid fibril formation, are determined. Based on the data of the amino acid sequence and the gene sequence thus obtained, an antibody is designed.

Abstract: An optical fiber is laid in a spiral shape on a surface of an iron skin of a hot-air oven constituting a blast furnace facility, and one end of the optical fiber is connected to a temperature measuring apparatus. A temperature distribution of an optical fiber laid area is measured based on the intensity of Raman back scattering light of a light pulse transmitted into the optical fiber and based on a time interval until the Raman back scattering light returns to the transmission end of the optical fiber. The temperature distribution is displayed on a display screen to monitor the temperature distribution of the whole area of the iron skin of the hot-air oven to detect an abnormal condition thereof.

Abstract: A liquid applicator structure which has an application tip fixed to front end of a cylindrical body and a liquid supply assembly built in its rear end. The liquid supply assembly includes a rotatable rod composed of a cylindrical shank-and-operating end and a solid rod having male threads thereon. The rotatable rod is held with an anti-rotation member having a cantilever-like extension. A split slide member having two split extensions is engaged with the rotatable rod at its rear end. One of these split extensions is inserted within the cantilever-like extension of the anti-rotation member and the rotatable rod, thereby preventing the split slide member from rotating. A piston member abuts on the split slide member. Rotation of the rotatable rod causes the split slide member and the piston to advance and drive liquid toward the application tip.